Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25-Report Released on 7th Nov
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Marinus Pharma (NASDAQ:MRNS) but lowers the price target from $32 to $25.
November 08, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Marinus Pharma but lowers the price target from $32 to $25.
The news is directly about Marinus Pharma. While the Buy rating is maintained, the lowering of the price target might indicate a potential decrease in the stock's value. However, the impact is neutral as the Buy rating suggests that the stock is still expected to perform well.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100